Effects of glycaemic management on diabetic kidney disease

Figure 1 Renal outcomes in the trial Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome. ¹Four-point renal outcome = progression to macroalbuminuria, doubling of serum creatinine, initiation of RRT or death from renal disease; ²Macroalbuminuria = albumin to creatinine ratio > 30 mg/mmol; ³Plus eGFR < 45 mL/min per 1.73 m². eGFR: Estimated glomerular filtration rate; HR: Hazard ratio; NS: Non statistically significant; RRT: Renal replacement therapy.

Figure 2 Cardiovascular outcomes in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome (A) and cardiovascular safety trial of empagliflozin (B) studies according to estimated glomerular filtration rate. MACE: Major adverse cardiovascular event; eGFR: Estimated glomerular filtration rate; HR: Hazard ratio.

Figure 3 Renal outcomes in the cardiovascular safety trial of empagliflozin study. ¹Four-point renal outcome = progression to macroalbuminuria plus three-point renal outcome; ²Three-point renal outcome = doubling of serum creatinine, initiation of RRT or death from renal disease; ³Macroalbuminuria = albumin to creatinine ratio > 30 mg/mmol; ⁴Plus eGFR < 45 mL/min per 1.73 m². HR: Hazard ratio; eGFR: Estimated glomerular filtration rate; CV: Cardiovascular; RRT: Renal replacement therapy.